BACKGROUND: neopterin is a monocyte/macrophage-derived immune activation marker and its levels increase with age. Frailty is an important clinical syndrome of old age. Previous studies have shown significant association between elevated interleukin-6 (IL-6) levels and frailty. The objective of this study was to evaluate IL-6-independent association of serum neopterin levels with prevalent frailty. METHODS: this is a cross-sectional study in community-dwelling older adults recruited from residential and retirement communities in Baltimore, MD, USA. Frailty was determined using validated screening criteria. Serum neopterin and IL-6 levels were measured using standard enzyme-linked immunosorbent assay. Pearson correlation and multivariate linear regression analysis was performed to assess the relationship between log(neopterin) and log(IL-6). Odds ratios (ORs) for frailty were calculated using log(neopterin) and log(IL-6) as continuous measures and across tertiles of neopterin and IL-6 levels, adjusting for age, race, sex, education and body mass index. RESULTS: one hundred and thirty-three individuals with a mean age of 84 years (range 72-97) completed the study. Neopterin levels were significantly higher in frail older adults than those in non-frail controls [median: 8.94 versus 8.35 nM, respectively, P < 0.001 t-test on log(neopterin)]. Log(neopterin) was significantly associated with prevalent frailty, adjusting for log(IL-6). Participants in the top tertile of neopterin had OR of 3.80 [95% confidence interval (CI) = 1.36-10.6, P < 0.01] for frailty. As expected, participants in the top tertile of IL-6 had OR of 3.29 (95% CI = 1.21-7.86, P < 0.05) for frailty. Log(neopterin) correlated with log(IL-6) (correlation coefficient = 0.19, P < 0.05). Moreover, OR for participants in the top neopterin tertile remained significant after adjusting for IL-6 (OR = 3.97, 95% CI = 1.15-13.72, P < 0.05). CONCLUSION: elevated neopterin levels had IL-6-independent association with prevalent frailty, suggesting potential monocyte/macrophage-mediated immune activation in the frail elderly.
BACKGROUND:neopterin is a monocyte/macrophage-derived immune activation marker and its levels increase with age. Frailty is an important clinical syndrome of old age. Previous studies have shown significant association between elevated interleukin-6 (IL-6) levels and frailty. The objective of this study was to evaluate IL-6-independent association of serum neopterin levels with prevalent frailty. METHODS: this is a cross-sectional study in community-dwelling older adults recruited from residential and retirement communities in Baltimore, MD, USA. Frailty was determined using validated screening criteria. Serum neopterin and IL-6 levels were measured using standard enzyme-linked immunosorbent assay. Pearson correlation and multivariate linear regression analysis was performed to assess the relationship between log(neopterin) and log(IL-6). Odds ratios (ORs) for frailty were calculated using log(neopterin) and log(IL-6) as continuous measures and across tertiles of neopterin and IL-6 levels, adjusting for age, race, sex, education and body mass index. RESULTS: one hundred and thirty-three individuals with a mean age of 84 years (range 72-97) completed the study. Neopterin levels were significantly higher in frail older adults than those in non-frail controls [median: 8.94 versus 8.35 nM, respectively, P < 0.001 t-test on log(neopterin)]. Log(neopterin) was significantly associated with prevalent frailty, adjusting for log(IL-6). Participants in the top tertile of neopterin had OR of 3.80 [95% confidence interval (CI) = 1.36-10.6, P < 0.01] for frailty. As expected, participants in the top tertile of IL-6 had OR of 3.29 (95% CI = 1.21-7.86, P < 0.05) for frailty. Log(neopterin) correlated with log(IL-6) (correlation coefficient = 0.19, P < 0.05). Moreover, OR for participants in the top neopterin tertile remained significant after adjusting for IL-6 (OR = 3.97, 95% CI = 1.15-13.72, P < 0.05). CONCLUSION: elevated neopterin levels had IL-6-independent association with prevalent frailty, suggesting potential monocyte/macrophage-mediated immune activation in the frail elderly.
Authors: Monique E Spencer; Alka Jain; Amy Matteini; Brock A Beamer; Nae-Yuh Wang; Sean X Leng; Naresh M Punjabi; Jeremy D Walston; Neal S Fedarko Journal: J Gerontol A Biol Sci Med Sci Date: 2010-05-17 Impact factor: 6.053
Authors: Linda P Fried; Qian-Li Xue; Anne R Cappola; Luigi Ferrucci; Paulo Chaves; Ravi Varadhan; Jack M Guralnik; Sean X Leng; Richard D Semba; Jeremy D Walston; Caroline S Blaum; Karen Bandeen-Roche Journal: J Gerontol A Biol Sci Med Sci Date: 2009-06-30 Impact factor: 6.053
Authors: Heidi N Schmaltz; Linda P Fried; Qian-Li Xue; Jeremy Walston; Sean X Leng; Richard D Semba Journal: J Am Geriatr Soc Date: 2005-05 Impact factor: 5.562
Authors: Tao Qu; Jeremy D Walston; Huanle Yang; Neal S Fedarko; Qian-Li Xue; Brock A Beamer; Luigi Ferrucci; Noel R Rose; Sean X Leng Journal: Mech Ageing Dev Date: 2008-11-05 Impact factor: 5.432
Authors: Christine K Liu; Asya Lyass; Martin G Larson; Joseph M Massaro; Na Wang; Ralph B D'Agostino; Emelia J Benjamin; Joanne M Murabito Journal: Age (Dordr) Date: 2015-12-23
Authors: Chris P Verschoor; Avee Naidoo; Jessica G Wallace; Jennie Johnstone; Mark Loeb; Jonathan L Bramson; Dawn Me Bowdish Journal: Inflammation Date: 2015-02 Impact factor: 4.092
Authors: Mara A McAdams-DeMarco; Hao Ying; Alvin G Thomas; Fatima Warsame; Ashton A Shaffer; Christine E Haugen; Jacqueline M Garonzik-Wang; Niraj M Desai; Ravi Varadhan; Jeremy Walston; Silas P Norman; Dorry L Segev Journal: Transplantation Date: 2018-10 Impact factor: 4.939
Authors: Kristine M Erlandson; Amanda A Allshouse; Catherine M Jankowski; Eric J Lee; Kevin M Rufner; Brent E Palmer; Cara C Wilson; Samantha MaWhinney; Wendy M Kohrt; Thomas B Campbell Journal: J Infect Dis Date: 2013-04-04 Impact factor: 5.226